These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 7185536)
21. Erythromycin-induced hypoacusis: 11 new cases and literature review. Sacristán JA; Soto JA; de Cos MA Ann Pharmacother; 1993; 27(7-8):950-5. PubMed ID: 8364281 [TBL] [Abstract][Full Text] [Related]
22. Recovery from cisplatin-induced ototoxicity: a case report and review. Truong MT; Winzelberg J; Chang KW Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797 [TBL] [Abstract][Full Text] [Related]
24. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266 [TBL] [Abstract][Full Text] [Related]
25. [Monitoring drug ototoxicity with distortion products]. Orts Alborch M; Morant Ventura A; García Callejo J; Ferrer Baixauli F; Martínez Beneito MP; Marco Algarra J Acta Otorrinolaringol Esp; 2000; 51(5):387-95. PubMed ID: 11000679 [TBL] [Abstract][Full Text] [Related]
26. Ototoxicity of erythromycin in man: electrophysiologic approach. Sacristán JA; Angeles De Cos M; Soto J; Zurbano F; Pascual J; Tasis A; Valle R; De Pablos C Am J Otol; 1993 Mar; 14(2):186-8. PubMed ID: 8503495 [TBL] [Abstract][Full Text] [Related]
27. Carbon monoxide poisoning and sensorineural hearing loss. Shahbaz Hassan M; Ray J; Wilson F J Laryngol Otol; 2003 Feb; 117(2):134-7. PubMed ID: 12625889 [TBL] [Abstract][Full Text] [Related]
28. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Karmody CS; Weinstein L Ann Otol Rhinol Laryngol; 1977; 86(1 Pt 1):9-11. PubMed ID: 835977 [TBL] [Abstract][Full Text] [Related]
29. [Medicamentous test for the screening of pharmacogenic risk of aminoglycoside ototoxicity]. Abakarov MG; Magomedov MM; Belousov IuB; Gotovskiĭ MIu Vestn Otorinolaringol; 2008; (6):48-51. PubMed ID: 19156118 [TBL] [Abstract][Full Text] [Related]
30. [Hearing loss after erythromycin therapy]. Lind O; Harthug S Tidsskr Nor Laegeforen; 1993 Sep; 113(22):2810-1. PubMed ID: 8211901 [TBL] [Abstract][Full Text] [Related]
31. Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation. Kobayashi K; Oguchi T; Asamura K; Miyagawa M; Horai S; Abe S; Usami S Auris Nasus Larynx; 2005 Jun; 32(2):119-24. PubMed ID: 15917167 [TBL] [Abstract][Full Text] [Related]
33. Ototoxicity after use of neomycin eardrops is unrelated to A1555G point mutation in mitochondrial DNA. Yamasoba T; Tsukuda K J Laryngol Otol; 2004 Jul; 118(7):546-50. PubMed ID: 15318963 [TBL] [Abstract][Full Text] [Related]
34. Protective effect of edaravone against tobramycin-induced ototoxicity. Asplund MS; Lidian A; Linder B; Takumida M; Anniko M Acta Otolaryngol; 2009 Jan; 129(1):8-13. PubMed ID: 18607936 [TBL] [Abstract][Full Text] [Related]
35. Ototoxic liability of erythromycin and analogues. Brummett RE Otolaryngol Clin North Am; 1993 Oct; 26(5):811-9. PubMed ID: 8233490 [TBL] [Abstract][Full Text] [Related]